EANS-Adhoc: AGENNIX AG /dievini Hopp BioTech Holding and Related Persons and Entities Granted Exemption from Mandatory Tender Offer for Agennix AG

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Litigation & Regulations

04.11.2010

Planegg/Munich (Germany), November 4, 2010 - Agennix AG (Frankfurt
Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) was informed
yesterday that the German Federal Financial Supervisory Authority
(Bundesanstalt fuer Finanzdienstleistungsaufsicht) (BaFin) has
yesterday granted the Company´s largest shareholder, dievini Hopp
BioTech holding GmbH & Co. KG ("dievini"), and certain other persons
and legal entities to whom dievini´s share ownership is attributed,
an exemption from the obligations pursuant to Section 35 of the
German Takeover Act to publish the acquisition of control, to provide
BaFin an offer document, and to publish a mandatory tender offer to
the other shareholders of Agennix AG in connection with the capital
increase of the Company completed in October 2010.

As a result of their participation in the capital increase completed
on October 4, 2010, dievini and certain other persons and legal
entities to whom dievini´s share ownership is attributed, acquired
control of the Company in the meaning of Section 29 (2) of the German
Takeover Act and would have been required to make a mandatory tender
offer to the other shareholders of Agennix had the exemption not been
granted.

end of ad-hoc-announcement ==========================================
====================================== About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company’s most
advanced program is talactoferrin, an oral therapy that has
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer, as well as in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program
further for the treatment of severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase
inhibitor in Phase I testing, and a topical gel form of talactoferrin
for diabetic foot ulcers. Agennix’s registered seat is in Heidelberg,
Germany. The Company has three sites of operation: Planegg/Munich,
Germany; Princeton, New Jersey and Houston, Texas. For additional
information, please visit the Agennix Web site at www.agennix.com.

This ad hoc announcement contains forward-looking statements, which
express the current beliefs and expectations of the management of
Agennix AG. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this ad hoc announcement.
Forward-looking statements speak only as of the date on which they
are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Investor Relations & Corporate Communications

Tel.: +49 (0) 89 8565 2693

E-Mail: ir@agennix.com

In the U.S.: Laurie Doyle

Director, Investor Relations & Corporate Communications

Phone: +1 609 524 5884

laurie.doyle@agennix.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade